Hansoo Michael Keyoung
CIK: 0001824764
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KAPA
Kairos Pharma, LTD.
Director
Discretionary Trading P&L
Holdings
About Keyoung Hansoo Michael
Keyoung Hansoo Michael (SEC CIK 0001824764) files insider reports with the SEC as Director of Kairos Pharma, LTD. (KAPA).
Signal8 holds 2 ownership filings by Keyoung Hansoo Michael (1 Form 3, 1 Form 4), filed between Sep 24, 2024 and Nov 26, 2025. Those filings report 2 transactions, from Sep 16, 2025 to Oct 8, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Keyoung Hansoo Michael's filings is in LOS ANGELES, CA.
Recent filings by Keyoung Hansoo Michael
Other insiders filing for Kairos Pharma, LTD. (KAPA)
- Bhowmick Neil, Chief Scientific Officer
- Bae Hyun W., Director
- Murali Ramachandran, VP of Research and Development
- Singhvi Rahul, Director
- Samuelson Doug, Chief Financial Officer
- Yu John S, CEO and Chairman